Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Comparison of Classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.

Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS.

Arch Pathol Lab Med. 2013 Dec;137(12):1740-6. doi: 10.5858/arpa.2012-0447-OA.

PMID:
24283854
2.

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study.

Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):254-9. doi: 10.1038/pcan.2013.10. Epub 2013 Apr 9.

PMID:
23567655
3.

Genome-wide association study identifies genetic determinants of urine PCA3 levels in men.

Chen Z, Sun J, Kim ST, Groskopf J, Feng J, Isaacs WB, Rittmaster RS, Condreay LD, Zheng SL, Xu J.

Neoplasia. 2013 Apr;15(4):448-53.

4.

Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.

Jin G, Zheng SL, Lilja H, Kim ST, Tao S, Gao Z, Young T, Wiklund F, Feng J, Isaacs WB, Rittmaster RS, Gronberg H, Condreay LD, Sun J, Xu J.

Neoplasia. 2013 Jan;15(1):95-101.

5.

Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men.

Jin G, Sun J, Kim ST, Feng J, Wang Z, Tao S, Chen Z, Purcell L, Smith S, Isaacs WB, Rittmaster RS, Zheng SL, Condreay LD, Xu J.

Hum Mol Genet. 2012 Dec 1;21(23):5222-8. doi: 10.1093/hmg/dds361. Epub 2012 Aug 30.

6.

A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Newcombe PJ, Reck BH, Sun J, Platek GT, Verzilli C, Kader AK, Kim ST, Hsu FC, Zhang Z, Zheng SL, Mooser VE, Condreay LD, Spraggs CF, Whittaker JC, Rittmaster RS, Xu J.

Genet Epidemiol. 2012 Jan;36(1):71-83. doi: 10.1002/gepi.21600.

7.

Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J.

Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12.

8.

Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

Thomas JA 2nd, Gerber L, Bañez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):576-81. doi: 10.1158/1055-9965.EPI-11-1017. Epub 2012 Feb 7.

9.

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS.

Lancet. 2012 Mar 24;379(9821):1103-11. doi: 10.1016/S0140-6736(11)61619-X. Epub 2012 Jan 24.

PMID:
22277570
10.

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS.

J Urol. 2011 Oct;186(4):1313-8. doi: 10.1016/j.juro.2011.05.071. Epub 2011 Aug 17.

PMID:
21849186
11.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.

Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

PMID:
21820580
12.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
13.

Diabetes and prostate cancer risk in the REDUCE trial.

Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ.

Prostate Cancer Prostatic Dis. 2011 Dec;14(4):326-31. doi: 10.1038/pcan.2011.28. Epub 2011 Jun 28.

PMID:
21709690
14.

Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R.

BJU Int. 2012 Apr;109(8):1162-9. doi: 10.1111/j.1464-410X.2011.10373.x. Epub 2011 Jun 23.

15.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.

BJU Int. 2011 Aug;108(3):388-94. doi: 10.1111/j.1464-410X.2011.10195.x. Epub 2011 Jun 1.

16.

Chemoprevention of prostate cancer.

Rittmaster RS.

Acta Oncol. 2011 Jun;50 Suppl 1:127-36. doi: 10.3109/0284186X.2010.527367. Review.

PMID:
21604953
17.

Biopsy misidentification identified by DNA profiling in a large multicenter trial.

Marberger M, McConnell JD, Fowler I, Andriole GL, Bostwick DG, Somerville MC, Rittmaster RS.

J Clin Oncol. 2011 May 1;29(13):1744-9. doi: 10.1200/JCO.2010.32.1646. Epub 2011 Mar 28.

18.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS.

Eur Urol. 2011 Feb;59(2):244-9. doi: 10.1016/j.eururo.2010.10.040. Epub 2010 Nov 4.

PMID:
21093145
19.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group.

J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12.

PMID:
21074214
20.

Low serum testosterone levels are poor predictors of sexual dysfunction.

Marberger M, Wilson TH, Rittmaster RS.

BJU Int. 2011 Jul;108(2):256-62. doi: 10.1111/j.1464-410X.2010.09766.x. Epub 2010 Oct 18.

21.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

22.

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.

Crawford ED, Andriole GL, Marberger M, Rittmaster RS.

Urology. 2010 Mar;75(3):502-9. doi: 10.1016/j.urology.2009.05.099. Epub 2009 Dec 29. Review.

PMID:
20035983
23.

Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.

Bostwick DG, Qian J, Drewnowska K, Varvel S, Bostwick KC, Marberger M, Rittmaster RS.

Urology. 2010 Jun;75(6):1406-10. doi: 10.1016/j.urology.2009.07.1348. Epub 2009 Nov 25.

PMID:
19942263
24.

Pharmacological approaches to reducing the risk of prostate cancer.

Rittmaster RS, Fleshner NE, Thompson IM.

Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Review.

PMID:
19200641
25.

Overexpression of 5 alpha-reductase type 1 increases sensitivity of prostate cancer cells to low concentrations of testosterone.

Thomas LN, Douglas RC, Rittmaster RS, Too CK.

Prostate. 2009 May 1;69(6):595-602. doi: 10.1002/pros.20911.

PMID:
19125422
26.

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

Rittmaster RS.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):389-402. doi: 10.1016/j.beem.2008.01.016. Review.

PMID:
18471794
27.

The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Tindall DJ, Rittmaster RS.

J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Epub 2008 Feb 20. Review. Erratum in: J Urol. 2008 Jun;179(6):2490.

28.

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS.

Eur Urol. 2008 Dec;54(6):1379-84. Epub 2007 Nov 20.

29.

Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.

Eur Urol. 2008 Feb;53(2):244-52. Epub 2007 Nov 5. Review.

PMID:
18006217
30.

Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.

Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS, Too CK.

J Urol. 2008 Jan;179(1):147-51. Epub 2007 Nov 13.

PMID:
17997435
31.

Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.

Nickel JC, Roehrborn CG, O'leary MP, Bostwick DG, Somerville MC, Rittmaster RS.

J Urol. 2007 Sep;178(3 Pt 1):896-900; discussion 900-1. Epub 2007 Jul 16.

PMID:
17632164
32.

Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development.

Lunacek A, Schwentner C, Oswald J, Fritsch H, Sergi C, Thomas LN, Rittmaster RS, Klocker H, Neuwirt H, Bartsch G, Radmayr C.

J Urol. 2007 Aug;178(2):716-21. Epub 2007 Jun 14.

PMID:
17574609
33.

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team.

J Am Acad Dermatol. 2006 Dec;55(6):1014-23.

PMID:
17110217
34.

DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.

Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wagenstaller J, Müller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM.

Nat Genet. 2006 Nov;38(11):1248-50. Epub 2006 Oct 8.

35.

Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS.

J Clin Endocrinol Metab. 2006 Apr;91(4):1323-8. Epub 2006 Jan 24.

PMID:
16434455
36.

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.

Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.

Urology. 2005 Jan;65(1):76-82.

PMID:
15667867
37.

Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.

Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, Rittmaster RS.

Prostate. 2005 May 15;63(3):231-9.

PMID:
15538746
38.

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.

Urology. 2004 Sep;64(3):537-41; discussion 542-3.

PMID:
15351586
39.

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS.

J Urol. 2004 Sep;172(3):915-9.

PMID:
15310997
40.

Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS.

Prostate. 2004 Feb 1;58(2):130-44.

PMID:
14716738
41.

5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.

Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, Thompson IM, Troyer DA, Rittmaster RS, Lazier CB.

J Urol. 2003 Nov;170(5):2019-25.

PMID:
14532845
42.

[Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].

Bartsch G, Rittmaster RS, Klocker H.

Urologe A. 2002 Sep;41(5):412-24. Review. German.

PMID:
12426858
43.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

World J Urol. 2002 Apr;19(6):413-25. Review.

PMID:
12022710
44.

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.

Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.

J Clin Endocrinol Metab. 2000 Jun;85(6):2129-34.

PMID:
10852440
45.

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

Bartsch G, Rittmaster RS, Klocker H.

Eur Urol. 2000 Apr;37(4):367-80. Review.

PMID:
10765065
46.
47.

The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer.

Rittmaster RS, Thomas LN, Wright AS, Murray SK, Carlson K, Douglas RC, Yung J, Messieh M, Bell D, Lazier CB.

J Urol. 1999 Dec;162(6):2165-9.

PMID:
10569613
48.

Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.

Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS.

Endocrinology. 1999 Oct;140(10):4509-15.

PMID:
10499505
49.

Antiandrogen treatment of polycystic ovary syndrome.

Rittmaster RS.

Endocrinol Metab Clin North Am. 1999 Jun;28(2):409-21. Review.

PMID:
10352926
50.

Supplemental Content

Loading ...
Support Center